摘要
目的探讨晚期氧化蛋白产物(AOPP)表达水平对冠心病介入治疗后发生再狭窄的影响。方法选取2017年4月—2019年4月于河南医学高等专科学校附属医院接受介入治疗的300例冠心病患者,记录患者年龄、性别、心血管病家族史、吸烟史等基本资料。对患者进行AOPP水平测定,根据测定结果将AOPP水平≤50.51μmol/L作为低AOPP组,>50.51μmol/L作为高AOPP组,比较不同AOPP水平患者指标及再狭窄发生率。用logistic回归法分析患者发生再狭窄的危险因素。结果AOPP测定结果显示,≤50.51μmol/L患者有158例,>50.51μmol/l有142例。两组年龄、心血管病家族史差异无统计学意义(P>0.05);高AOPP组吸烟史例数、Gensini积分、支架数≥3比例、支架直径及长度均高于低AOPP组(P<0.05)。随访1年期间,高AOPP组再狭窄发生率显著高于低AOPP组(P<0.05)。经logistic回归分析,AOPP>50.51μmol/L、支架数≥3、Gensini积分>20分及有吸烟史为患者介入治疗后发生再狭窄的危险因素。结论AOPP高水平表达是冠心病患者介入治疗后发生再狭窄的独立危险因素之一,可作为预测患者治疗后发生心脏不良事件的生化标记物,对临床具有参考价值。
Objective To investigate the effect of advanced oxidation protein product(AOPP)expression on restenosis of coronary heart disease patients after intervention.Methods 300 patients with coronary heart disease in the hospital from April,2017 to April,2019 were selected.Clinical data of age,gender,family history of cardiovascular disease and smoking history were recorded.Patients were divided into two groups according to AOPP levels,low AOPP group(≤50.51μmol/L)and high-AOPP group(>50.51μmol/L).The indicators and restenosis rate were compared between groups;then the risk factors of restenosis rate were verified by logistic regression analysis.Results There were 158 patients with AOPP≤50.51μmol/L,and 142 patients with AOPP>50.51μmol/L.There was no statistically significant difference in age and family history of cardiovascular disease between groups(P>0.05).The number of smoking history,Gensini score,number of stent≥3,stent diameter and stent length in the high AOPP group were higher than those in the low AOPP group(P<0.05).During the 1-year follow-up,the incidence of restenosis was significantly higher in the high AOPP group than in the low AOPP group(P<0.05).Logistic regression analysis showed that AOPP>50.51μmol/L,number of stents≥3,Gensini score>20 points,and history of smoking were risk factors for restenosis after interventional treatment.Conclusion High-level expression of AOPP is one of the independent risk factors for restenosis in patients with coronary heart disease after interventional therapy,which can be used as a biochemical marker to predict the occurrence of cardiac adverse events in patients after treatment.So it is worth references.
作者
岳威位
张彦周
樊鑫钰
YUE Wei-wei;ZHANG Yan-zhou;FAN Xin-yu(Cardiology,Affiliated Hospital of Henan Medical College,Zhengzhou,451191,China)
出处
《黑龙江医学》
2020年第10期1326-1329,共4页
Heilongjiang Medical Journal
关键词
晚期氧化蛋白产物
表达水平
冠心病介入治疗
再狭窄
Advanced oxidation protein product
Expression level
Coronary heart disease intervention
Restenosis
